AbbVie and Momenta announce Humira patent licence agreement

08-11-2018

AbbVie and Momenta announce Humira patent licence agreement

Artur / iStockphoto.com

Biotech company Momenta has obtained the rights to use AbbVie’s Humira (adalimumab) IP, enabling the global commercialisation of Momenta’s proposed Humira biosimilar, M923.


AbbVie, Momenta, patent license agreement, Humira, arthritis, Crohn's disease, chronic psoriasis, royalties, biosimilar, European Medicines Agency, M923

LSIPR